Armata Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Armata Pharmaceuticals's earnings have been declining at an average annual rate of -29.2%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 52.1% per year.
Key information
-29.2%
Earnings growth rate
20.1%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 52.1% |
| Return on equity | n/a |
| Net Margin | -1,524.5% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Armata Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 5 | -69 | 12 | 0 |
| 30 Sep 23 | 4 | -60 | 10 | 0 |
| 30 Jun 23 | 4 | -37 | 8 | 0 |
| 31 Mar 23 | 5 | -43 | 8 | 0 |
| 31 Dec 22 | 6 | -37 | 7 | 0 |
| 30 Sep 22 | 5 | -33 | 8 | 0 |
| 30 Jun 22 | 5 | -29 | 8 | 0 |
| 31 Mar 22 | 5 | -26 | 8 | 0 |
| 31 Dec 21 | 4 | -23 | 8 | 0 |
| 30 Sep 21 | 4 | -24 | 8 | 0 |
| 30 Jun 21 | 3 | -24 | 8 | 0 |
| 31 Mar 21 | 2 | -23 | 8 | 0 |
| 31 Dec 20 | 1 | -22 | 8 | 0 |
| 30 Sep 20 | 0 | -20 | 10 | 0 |
| 30 Jun 20 | 0 | -21 | 11 | 0 |
| 31 Mar 20 | 0 | -21 | 11 | -2 |
| 31 Dec 19 | 0 | -19 | 10 | 0 |
| 30 Sep 19 | 0 | -16 | 8 | 1 |
| 30 Jun 19 | 0 | -12 | 5 | 2 |
| 31 Mar 19 | 0 | -11 | 4 | 7 |
| 31 Dec 18 | 0 | -17 | 4 | 7 |
Quality Earnings: TG1N is currently unprofitable.
Growing Profit Margin: TG1N is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TG1N is unprofitable, and losses have increased over the past 5 years at a rate of 29.2% per year.
Accelerating Growth: Unable to compare TG1N's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TG1N is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.9%).
Return on Equity
High ROE: TG1N's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.